ARS Pharmaceuticals
SPRY
SPRY
70 hedge funds and large institutions have $94.7M invested in ARS Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
53% less capital invested
Capital invested by funds: $200M → $94.7M (-$106M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
70
Holding in Top 10
–
Calls
$188K
Puts
$3K
Top Buyers
| 1 | +$4.21M | |
| 2 | +$1.06M | |
| 3 | +$953K | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$843K |
| 5 |
Two Sigma Advisers
New York
|
+$506K |
Top Sellers
| 1 | -$11.6M | |
| 2 | -$3.96M | |
| 3 | -$3.53M | |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.56M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.71M |